Cargando…
Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that leads to progressive weakness from loss of motor neurons and death on average in less than 3 years after symptom onset. No clear causes have been found and just one medication, riluzole, extends survival. Researchers have ident...
Autores principales: | Corcia, Philippe, Gordon, Paul H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431958/ https://www.ncbi.nlm.nih.gov/pubmed/22956874 http://dx.doi.org/10.2147/TCRM.S21981 |
Ejemplares similares
-
From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies
por: Mignani, Serge, et al.
Publicado: (2020) -
Current view and perspectives in amyotrophic lateral sclerosis
por: Mathis, Stéphane, et al.
Publicado: (2017) -
Elevated Serum Ferritin Is Associated with Reduced Survival in Amyotrophic Lateral Sclerosis
por: Nadjar, Yann, et al.
Publicado: (2012) -
Metabolomics: A Tool to Understand the Impact of Genetic Mutations in Amyotrophic Lateral Sclerosis
por: Lanznaster, Débora, et al.
Publicado: (2020) -
Dexpramipexole Is Ineffective in Two Models of ALS Related Neurodegeneration
por: Vieira, Fernando G., et al.
Publicado: (2014)